Follicular lymphoma is graded 1 to 3 based on how many large B cells (centroblasts) appear under a microscope, which signals how fast it may grow. Grade 1 and 2 follicular lymphoma are usually slow ...

—Researchers recently identified 2 distinct genetic subgroups in follicular lymphoma, shedding light on the factors influencing its transformation to diffuse large B-cell lymphoma. What are the ...

Follicular lymphoma is a slow-growing non-Hodgkin’s lymphoma that often causes no early symptoms. Swollen lymph nodes in the neck, armpits, groin, or thighs are usually the first sign. Symptoms can ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell ...

Credit: Getty Images. Odronextamab is an investigational CD20xCD3 bispecific antibody. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) ...

Monjuvi in combination with lenalidomide and rituximab significantly improved PFS in patients with relapsed/refractory follicular lymphoma. The Food and Drug Administration (FDA) has approved Monjuvi ...

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma. The Food and Drug ...

There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma that affects white blood cells called ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell ...